Santalis Pharmaceuticals, Inc.

Release Summary

Santalis Pharmaceuticals Enrolls First U.S. Subject Into a Phase 2 Clinical Study of Mild to Moderate Atopic Dermatitis

Santalis Pharmaceuticals, Inc.